Zhenhua Ren

List of Publications by Year
in descending order

16 papers	894 citations	759233 12 h-index	888059 17 g-index
18 all docs	18 docs citations	18 times ranked	1493 citing authors

#	Article	IF	Citations
1	Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. Journal of Clinical Investigation, 2022, 132, .	8.2	38
2	ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth. Cancer Research, 2021, 81, 174-186.	0.9	12
3	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer Cell, 2021, 39, 96-108.e6.	16.8	153
4	Dual targeting of CTLA-4 and CD47 on T _{reg} cells promotes immunity against solid tumors. Science Translational Medicine, 2021, 13, .	12.4	39
5	Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. Nature Immunology, 2020, 21, 546-554.	14.5	78
6	Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity. Cancer Cell, 2020, 38, 400-411.e6.	16.8	70
7	Abstract 973: Telomere stress potentiates host STING-dependent anti-tumor immunity. , 2020, , .		0
8	Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. Science Immunology, 2019, 4, .	11.9	30
9	Degradation of CTLA-4 balances toxicity and efficacy. Science Bulletin, 2019, 64, 1388-1389.	9.0	2
10	A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature Communications, 2019, 10, 3874.	12.8	132
11	Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis. Cancer Cell, 2019, 35, 901-915.e4.	16.8	98
12	Targeting IFNÎ± to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nature Communications, 2018, 9, 4586.	12.8	60
13	Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. Cell Reports, 2018, 24, 2101-2111.	6.4	90
14	CTLA-4 Limits Anti-CD20â€“Mediated Tumor Regression. Clinical Cancer Research, 2017, 23, 193-203.	7.0	35
15	Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression. Cancer Immunology Research, 2017, 5, 560-570.	3.4	10
16	PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment. Cancer Discovery, 2016, 6, 477-478.	9.4	41